The purpose of the present analysis was to identify predictors of procedural success of percutaneous transcatheter aortic valve implantation (TAVI).
Introduction
Transcatheter aortic valve implantation (TAVI) has rapidly been implemented as a new and less-invasive treatment option for patients with severe symptomatic aortic valve stenosis at high surgical risk. Since the first-in-man experience in 2002, 1 the technology has significantly improved with the development of smaller profile delivery catheters and better prostheses with availability of various sizes. Presently, two different techniques are commercially available: the balloon-expandable Edwards SAPIEN prosthesis (Edwards Lifesciences, Irvine, CA, USA) and the self-expanding CoreValve Revalving system (Medtronic, Minneapolis, MN, USA;
Figures 1 and 2). Both devices have been described in detail in previous publications, 1 -10 and more than 4000 patients have now been treated worldwide with one of these techniques. Data on procedural performance, safety, and efficacy are yet still limited. Using the latest devices in experienced centres, procedural success rates of up to 96% with a 30 day mortality rate of 7-12% have been reported, 8 -10 in patients deemed at high surgical risk with numerous co-morbidities. However, predictors of procedural success are not well established. As with all new techniques, there is an operator learning curve, which influences early outcome. This holds true particularly for TAVI, a demanding procedure with several new features compared with standard interventional techniques, such as dealing with a large arterial access, manoeuvring a large-profile device retrogradely through the aorta as well as the implantation steps of the prosthesis itself within the native, diseased aortic valve. Even if the operator is familiar with the technique, procedural success still varies over a wide range between 70 and 96%, 7 -10 indicating additional obstacles. Therefore, we aimed at identifying predictors of in-hospital procedural success, defined as successful device implantation without in-hospital major adverse cardiac and cerebral adverse events (MACCE).
Methods

Patient population
Between February 2005 and June 2008, 168 consecutive patients underwent TAVI using the CoreValve Revalving device (Figures 1 and  2 ) at two institutions with TAVI expertise, HELIOS Klinikum Siegburg, Siegburg, Germany (138 patients), and Bern University Hospital, Bern, Switzerland (30 patients). As the CoreValve Revalving prosthesis received European market approval in 2007, the present patient population encompasses patients included during the early safety and efficacy studies as well as post-approval registry patients.
Patient screening and eligibility
All patients underwent a pre-interventional screening process to determine eligibility. Coronary anatomy and haemodynamic status were evaluated by coronary angiography and complete left and right heart catheterization. The valvular anatomy was assessed using transthoracic and transoesophageal echocardiography, contrast angiography of the aortic root and multi-slice computer tomography (MSCT) of the thoracic aorta as the key screening methods. Annulus dimensions were obtained from three-dimensional multi-planar MSCT reformation due only to its accuracy and robustness in visualizing the region of interest with minimized artificial effects as opposed to echocardiography. Vascular access was assessed using MSCT of the abdominal aorta, and the iliac and femoral vessels. The baseline surgical risk was estimated by use of the logistic EuroSCORE. Eligibility of patients included into the safety and efficacy studies was dependent on the study-specific inclusion and exclusion criteria described elsewhere. 5, 7, 9 Patient eligibility of the post-approval series was similar to the safety and efficacy studies. Patients were considered suitable if they (i) fulfilled the anatomical requirements ( Figure 3 ) and (ii) were considered at high surgical risk as confirmed by a senior cardiologist and cardiac surgeon.
Device and procedure
Design characteristics of the self-expanding CoreValve Revalving prosthesis ( Figure 1 ) as well as the procedural characteristics have been described previously. 4, 5, 7, 9 Briefly, the CoreValve prosthesis consists of a tri-leaflet bioprosthetic porcine pericardial tissue valve, which is sutured into a self-expanding nitinol frame. The sizes of three subsequently developed delivery systems have been gradually reduced from 25 French (Generation 1) and 21 French (Generation 2) to 18 French (Generation 3) over time which facilitated vascular access and deployment of the device. For the current Generation 3 device, two different sizes are available accommodating annulus dimensions from 19 to 27 mm. While the implants of Generation 1 and majority of Generation 2 required surgical access to the iliac arteries requiring general anaesthesia, the Generation 3 device can be implanted percutaneously under sedoanalgesia. Vascular access can be obtained with standard percutaneous access techniques and percutaneous closure using a pre-loaded suture device (e.g. Prostar XL suture device, Abbott Vascular, Abbott Park, IL, USA).
After mandatory pre-dilation of the native aortic valve, the prosthesis is advanced retrogradely and deployed within the aortic annulus. 
Transcatheter aortic valve implantation
Statistical analysis
Potential predictors for in-hospital procedural success were divided into clinical, quantitative morphological, and procedural variables. Clinical variables included the parameters presence of congestive heart failure, diabetes, renal insufficiency (creatinine .1.2 mg/dL), smoking, arterial hypertension, pulmonary hypertension (mean pulmonary artery pressure at rest .25 mmHg), coronary artery disease, prior stroke, prior myocardial infarction, prior percutaneous coronary intervention (PCI), prior coronary artery bypass grafting, pre-procedural New York Heart Association (NYHA) class, pre-procedural Karnofsky index (see Appendix), 11 and logistic EuroSCORE. Quantitative morphological variables included pre-procedural aortic regurgitation, preprocedural peak aortic valve gradient, pre-procedural mean aortic valve gradient, pre-procedural mean aortic valve area, left ventricular ejection fraction, and annulus diameter by MSCT. Procedural variables included use of a large prosthesis, pre-dilation balloon diameter, postdilation performed, post-dilation balloon diameter, access (femoral, iliac, subclavian artery). Details on parameter characteristics are listed in Appendix 1. Categorical variables are presented as frequencies and were compared by chi-square test or Fisher's exact test. Continuous variables are presented as mean + standard deviation and were compared by unpaired Student's t-test. Univariate logistic regression was performed on all variables to identify determinants for in-hospital procedural success, in-hospital major adverse cardiac and cerebrovascular events (MACCE), and death. A P-value of ,0.20 at the univariate stage was the method of selection of potential predictive factors in the comparison of incidence rates. Next, relationships of event incidence to selected covariates were investigated with multivariate logistic regression models. All statistical tests were bilateral and a P-value of ,0.05 was considered significant in the final modelling.
Statistical analyses were conducted by Medpass International, Paris, France. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agreed to the manuscript as written. All patients provided written informed consent prior to the procedure. The study as well as informed consent procedures were approved by the local ethics committees at each institution.
Outcome definitions
In-hospital procedural success was defined as device success with the absence of MACCE during the in-hospital period. Acute procedural success was defined as device success with the absence of periprocedural MACCE during the first 24 h after device implantation. Device success was defined as stable device placement and adequate function without severe aortic regurgitation during the first attempt as assessed by angiography and echocardiography. MACCE consisted of death from any cause, myocardial infarction (creatine kinasemyocardial band more than two times the upper limit of normal; measured routinely post procedure and on Day 1 as well as in case of clinical need), and stroke (as assessed by routine neurological assessment before and after procedure and before hospital discharge). Clinical adverse events were adjudicated by an independent clinical events committee.
Results
Patient population
Patient baseline and procedural characteristics are listed in Table 1 . A total of 168 patients out of 380 patients with aortic valve stenosis and high surgical risk entering the MSCT screening process underwent TAVI at two institutions and were included in this analysis. In 14.2% of screened patients, eligibility criteria were fulfilled and TAVI procedure was intended, but not yet performed, during the study period. Patients were not eligible for the TAVI procedure due to inadequate annulus sizes (27.2%, with annulus range inclusion criterion of '20 -23 mm', early one device size generation; 4.2%, with annulus range inclusion criterion of '20 -27 mm', current two device size generations), peripheral artery disease (19.8%), excessive valve calcifications (2.4%), and aneurysms of the ascending aorta (1.4%). Surgical valve replacement was performed in 12.3% of patients without TAVI exclusion criteria based on the interdisciplinary clinical judgment, and in 21.2% of patients, the TAVI procedure was not performed due to lack of clinical indication (including reduced life expectancy for other reasons, bleeding risk) or patient preferences.
The mean patient age of patients undergoing TAVI was 81.9 + 6.7 years. Pre-procedural functional status as assessed by the Karnofsky index (functional performance scale, see Appendix) was 10 -40 (severely reduced) in 48% of these patients, mean 44.8, median 50, range 20 -80. Patients were severely symptomatic (NYHA class III/IV: 93% of patients) with a mean aortic valve area of 0.66 + 0.21 cm 2 , mean pressure gradient was 43.2 + 16.9 mmHg. None or mild pre-procedural aortic regurgitation was present in 80.8% of patients.
Acute and in-hospital outcome
The acute and in-hospital procedural success rates in the study population were 90.5 and 83.9%, respectively ( Table 2) . The in-hospital MACCE rate was 16.7%, with an in-hospital mortality, myocardial infarction, and stroke rate of 11.9, 1.8, and 3.6%, respectively. In-hospital mortality was primarily related to progressive heart failure, dominantly right heart failure, as well as pneumonia, sepsis, and mesenterial infarction. Acute device success was observed in 93.5%.
Univariate and multivariate analyses
Results of the univariate and multivariate analyses are presented in Tables 3 -8 . Univariate analysis identified two potential clinical predictors [pre-procedural Karnofsky index, odds ratio (OR) 1.04, 95% confidence interval (CI) 1.01-1.08, P ¼ 0.01; prior PCI, OR 5.3, 95% CI 1.20-23.41, P ¼ 0.028; Table 3 ] and one procedural predictor (access site, OR 0.33, 95% CI 0.13-0.82, P ¼ 0.017; Table 5 ) for in-hospital procedural success. In the multivariate analysis, pre-procedural Karnofsky index emerged as the only independent predictor for in-hospital procedural success (OR 1.04, 95% CI 1.00 -1.08, P ¼ 0.032; Table 6 ). There was a trend for the variable access site (OR 0.48, 95% CI 0.18 -1.27, P ¼ 0.139), but this did not reach significance in the multivariate analysis. The multivariate predictor analysis for any major adverse event including death, stroke, and myocardial infarction-as part of in-hospital success-as well as mortality alone revealed a predictive impact of the pre-procedural Karnofsky index (any MACCE: OR 0.98, 95% CI 0.93-1.00, P ¼ 0.025; death alone: OR 0.97, 95% CI 0.93-1.00, P ¼ 0.051; Tables 7 and 8).
Discussion
Transcatheter aortic valve implantation success is influenced by numerous factors, including operator experience and patient selection. Particularly, the operator learning curve affects the outcome in the first cases of each centre. However, even beyond this learning period, procedural outcome varies, with procedural failure rates of approximately 5-25%. 7 -9 Therefore, it is of importance to identify factors which predict the outcome of TAVI in clinical practice.
We have analysed various clinical, quantitative morphological, and procedural parameters potentially affecting procedural outcome based on the combined TAVI experience of two institutions. In-hospital procedural success was chosen as the principal outcome parameter, as it reflects a combination of feasibility, safety, and efficacy in a clinically relevant way, indicating the amount of patients discharged after TAVI without major complications including death, stroke, or myocardial infarction.
The in-hospital procedural success rate amounted to 83.9% in the present report, with an acute device and procedural success rate of 93.5 and 90.5%, respectively, which is in line with previous publications. 8 -10 The only independent predictive parameter of in-hospital procedural success was the pre-procedural functional performance status of the patient, as expressed in our study by the Karnofsky Transcatheter aortic valve implantation index-though the effect was mild just reaching significance. This observation is primarily driven by a significant influence of the preprocedural Karnofsky index on the incidence of MACCE, namely the rate of death. The univariate analysis identified the access site as another potential predictor for in-hospital procedural success without significance in the multivariate analysis. In other words, the in-hospital outcome might have been partially affected by the selection of the access site, favouring the femoral over the iliac and subclavian access. However, the number of patients with non-femoral access is comparatively low, limiting the ability to draw meaningful conclusions from this finding. This observation of a predictive effect of the Karnofsky index is of importance for future TAVI studies, as it might shift the clinical relevance of scoring systems from the historically used, more co-morbidity-based EuroScore or Society of Thoracic Surgeons (STS) score towards functional assessment scales (frailty indices). Accordingly, it is not the sum of various individual co-morbidities that predicts the procedural risk, but rather their consequences on the functional and clinical status of the patient. This finding is not surprising-a frail patient usually has a slower and more complicated recovery than a physically healthy one-but its impact on procedural success and in-hospital mortality has not previously been validated in the field of TAVI.
In this study, we have chosen the Karnofsky index as functional performance scale, which originates from the field of oncology owing to its simplicity. However, there are multiple functional Table 3 Univariate predictor analysis for in-hospital procedural success of transcatheter aortic valve implantationclinical predictors Table 4 Univariate predictor analysis for in-hospital procedural success of transcatheter aortic valve implantationmorphological predictors Table 5 Univariate predictor analysis for in-hospital procedural success of transcatheter aortic valve implantationprocedural predictors Table 6 Multivariate predictor analysis for in-hospital procedural success of transcatheter aortic valve implantation Table 7 Multivariate predictor analysis for any in-hospital major adverse cardiac and cerebral adverse events after transcatheter aortic valve implantation Table 8 Multivariate predictor analysis for in-hospital death after transcatheter aortic valve implantation performance scales available, which might be valuable as well. Additional studies on larger patient populations focusing on this important aspect are certainly needed to confirm this finding.
The result of the univariate analysis with a predictive value of the type of access site, favouring femoral access over iliac and subclavian access, helps to understand the improvement of published outcome rates over the past few years. The main benefit of the profile size reduction of the CoreValve prosthesis from Generation 1 (25 French) over Generation 2 (21 French) to the Generation 3 (18 French) was to allow the shift of access site from a more central location-iliac-to a more peripheral-femoralposition. This resulted in the ability to perform the procedure in a truly percutaneous fashion, without the risk of complications associated with the access surgery-which was required to open as well as close the iliac artery-or the accompanying general anaesthesia. However, these technical changes did not affect the predictive importance of the patient's functional condition as shown above.
If confirmed in larger studies, the finding of a correlation of preprocedural frailty and post-procedural outcome might be important for future studies in the field of TAVI as it may open the door towards inclusion of lower-risk patients as presently enrolled. Up to now, it has been uncertain whether a complication after TAVI was procedure-related or mainly related to the patient's preprocedural functional status and co-morbidities. The present data support the notion that the healthier the patient is before the procedure the better is his outcome after TAVI. Accordingly, complication and success rates of TAVI as currently reported in patients at high surgical risk cannot be translated to lower risk patients with a good functional performance status. TAVI in patients at low surgical risk might yield better feasibility and safety results than the presently reported ones.
Limitations
The present analysis is based on consecutive cohorts of two centres with considerable TAVI experience. Notwithstanding, the overall number of patients is small, which might affect the validity of the predictor analysis due to lack of sufficient power particularly with respect to the detection of confounding factors. Larger studies are needed to confirm these findings. To expand the overall patient population, the entire TAVI cohort has been included in both centres, also comprising the patients of the learning phase as well as the patients included during the evaluation of first-and second-generation devices at HELIOS Heart Center Siegburg. Exclusion of these patients would have limited the event numbers and hence the ability to perform the predictor analysis. Only the self-expanding CoreValve Revalving prosthesis has been studied in this analysis. Separate studies are needed to confirm these findings for patients treated with a balloonexpandable aortic valve prosthesis. The Karnofsky index has been chosen for assessment of the functional patient status which has not been validated in patients undergoing TAVI. Other frailty scores might be more suitable to assess the patient performance. However, none of the presently available scoring systems are validated in this new field of interventional cardiology. The STS score was calculated retrospectively in the study patient population and added for descriptive purposes in the patient characteristic table, but was not considered as a parameter in the present analysis. Since the focus of this analysis was prediction of MACCE with relevant clinical sequelae, namely death, stroke, and myocardial infarction, we did not include complications such as need for pacemaker or bleeding in our success definition. 10 Moribund; fatal processes progressing rapidly. 0 Dead
